Archive

Advances in RRMM

Written by Alex Burton | 9 May 2019

Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study

State of the art clinical trials

Written by Alex Burton | 6 May 2019

Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).

EHA 2018: OPTIMISMM

Written by Karen Ramirez | 24 Jun 2018

Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by Karen Ramirez | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by Karen Ramirez | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

Real-world data shows details beyond the clinical trials

Written by Karen Ramirez | 21 Feb 2018

Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.

ASH Highlights (Myeloma)

Written by Karen Ramirez | 13 Feb 2018

As usual, there was a lot of new data in at ASH 2017 in myeloma. Above Professor S Vincent Rajkumar (Mayo Clinic, Rochester, USA) gives a great overview of… read more.

BSH 2017: How I treat molecular high-risk myeloma – what can we do, what should we do?

Written by Karen Ramirez | 6 Apr 2017

High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.

BSH 2017: Are we ready to use minimum residual disease to direct therapy?

Written by Karen Ramirez | 4 Apr 2017

Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Written by Lorraine Carolan | 19 Jul 2016

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Written by Lorraine Carolan | 2 Jun 2016

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article ‘Risk stratification in the older patient: what are our priorities?’

Written by Lorraine Carolan | 31 May 2016

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

1 2 Next »

Archive

Subscribe for our mailing list

Follow Us